Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):279-88

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  RADIOIMMUNOTHERAPY
Guest Editor: S. J. Mather
 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):279-88

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Engineered single chain antibody fragments for radioimmunotherapy

Huhalov A., Chester K. A.

Cancer Research UK Imaging and Targeting Group Department of Oncology, Royal Free and University College Medical School, Royal Free Campus London, United Kingdom


PDF


An ideal molecule to deliver radioimmunotherapy (RIT) would be target specific and have prolonged residence time at high concentrations in the tumour with rapid clearance from normal tissues. It would also be non-immunogenic. These features can be rationally introduced into recombinant antibody-based proteins using antibody engineering techniques. This review focuses on the use of antibody engineering in the design and development of RIT molecules which have single chain Fv (scFv) antibody fragments as building blocks.

top of page